<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/217101-process-for-preparing-an-orally-administrable-pharmaceutical-formulation by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 11:22:56 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 217101:&quot;PROCESS FOR PREPARING AN ORALLY ADMINISTRABLE PHARMACEUTICAL FORMULATION&quot;</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">&quot;PROCESS FOR PREPARING AN ORALLY ADMINISTRABLE PHARMACEUTICAL FORMULATION&quot;</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The present invention relates to a pharmaceutical formulation for oral administration through a soft gelatin capsule drug delivery device, wherein the said pharmaceutical formulation comprises essentially of Pseudoephedrine HCI as the active ingredient. The active pharmaceutical ingredient is embedded into an oily matrix, also the formulation comprises of viscosity imparting agents, a surfactant; a suspending agent; and a suspension medium. The viscosity-imparting agents are partially hydrogenated vegetable oil and colloidal silicon dioxide, the surfactant is lecithin, the suspending agent is yellow beeswax, and the suspension medium is soybean oil. The formulation comprises of about 60 mg by weight of Pseudoephedrine HCI, about15-25 mg by weight of partially hydrogenated vegetable oil, about 10-20 mg by weight of yellow beeswax, about 2-8 mg by weight of lecithin, about 2-8 mg by weight of silicon dioxide; and about 150-250 mg by weight of soybean oil. Also the invention is addressed at the process for preparing the formulation.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>ORALLY ADMINISTRABLE PHARMACEUTICAL FORMULATION<br>
Background of the Invention<br>
Field of the Invention<br>
[001]	This   invention   in   general   relates   to   orally   administrable<br>
pharmaceutical formulations and in particular to a pharmaceutical formulation prepared into a soft gelatin capsule containing Pseudoephedrine Hydrochloride as the active ingredient.<br>
Description of the Related Art<br>
[002]	Pseudoephedrine Hydrochloride is a drug that has got serious<br>
abuse potential. This is so because Pseudoephedrine or Ephedrine could be extracted from various drug products containing Pseudoephedrine Hydrochloride and can be converted into amphetamines. Amphetamines have potentially lethal stimulant effects on the central nervous system and heart and it is thereof important if such abuse potential could be minimized.<br>
[003]	The patient compliance is improved if soft gelatin capsule is<br>
used for drug administration, because of its soft, elastic character making it easier to swallow when compared to conventional tablets or hard gelatin capsules.<br>
[004]	Further more, since the dosage form is generally swallowed, it is<br>
unnecessary to flavor or otherwise mask any unpleasant taste of the active pharmaceutical ingredients. Finally unlike tablets, soft gelatin capsules do not chip or powder.<br>
[005]	Pseudoephedrine HCI is a vasoconstrictor, which  produces<br>
vasoconstriction by stimulating (alpha)-receptors within the mucous of the respiratory tract. Clinically Pseudoephedrine shrinks the swollen mucous membranes, reduces tissue hyperemia, edema and nasal congestion, and increases nasal airway patency. Its use is therefore significant in the relief from nasal congestion.<br>
[006]	Pseudoephedrine HCI tablets used for the temporary relief of<br>
nasal congestion caused by common cold are commercially available in various strengths. However, soft gelatin formulations comprising Pseudoephedrine HCI are not commercially available. The following table contains details of commercially available soft gelatin formulations comprising Pseudoephedrine HCI or Pseudoephedrine in combination of antihistamines or analgesics.<br>
Active Ingredient/s	Brand Name / Manufacturer<br>
(Each Capsule contains)<br>
Pseudoephedrine H Cl         Nyquil /<br>
30mg	Proctor &amp; Gamble<br>
Doxylamine succinate<br>
6.25mg<br>
Dextromethorphan H Br<br>
10mg<br>
Acetaminophen 200mg<br>
Pseudoephedrine H Cl         Dayquil /<br>
30mg	Proctor &amp; Gamble<br>
Dextromethorphan H Br<br>
10mg<br>
Acetaminophen 200mg<br>
Pseudoephedrine HCI	Alka-Seltzer Plus<br>
30mg	Night-Time Cold Medicine<br>
Doxylamine succinate	Bayer<br>
6.25mg<br>
Dextromethorphan H Br<br>
10mg<br>
Acetaminophen 325mg<br>
Pseudoephedrine H Cl         Alka-Seltzer Plus<br>
30mg	Cold &amp; Cough Medicine<br>
Chlorpheniramine Maleate   Bayer<br>
2mg<br>
Dextromethorphan H Br<br>
10mg<br>
Acetaminophen 325mg<br>
Pseudoephedrine H Cl	Alka-Seltzer Plus<br>
30mg	Cold &amp; Cough Medicine<br>
Chlorpheniramine Maleate	Bayer<br>
2mg<br>
Acetaminophen 325mg<br>
Pseudoephedrine H Cl	Alka-Seltzer Plus<br>
30mg    Chlorpheniramine   Cold &amp; Cough Medicine<br>
Maleate 2mg	Bayer<br>
Acetaminophen 325mg<br>
Pseudoephedrine H Cl	Alka-Seltzer Plus<br>
30mg  Acetaminophen	Cold &amp; Sinus Medicine<br>
325mg	Bayer<br>
Pseudoephedrine H Cl	Alka-Seltzer Plus<br>
30mg Dextromethorphan	Cold &amp; Cough Medicine<br>
HBMOmg	Bayer<br>
Acetaminophen 325mg<br>
[007]	U.   S.   Patent   5,409,907   to   Blase   et.   al   describes   a<br>
pharmaceutical suspension comprising a therapeutic amount of pharmaceutical active selected from the group consisting of acetaminophen, famotidine, pseudoephedrine hydrochloride, Chlorpheniramine maleate, astemizole, dextromethorphan hydrobromide, guaifenesin, diphenhydramine hydrochloride, loperamide hydrochloride, simethicone, antacids, and combinations thereof. However, the suspending system described herein comprises of an effective amount of xanthan gum and microcrystalline cellulose. The current invention has employed a different suspension medium and a suspending agent.<br>
[008]	A composition  including  soybean  oil,  yellow beeswax and<br>
lecithin has been disclosed in the U.S Patent 6,309,667 to Horvath et. al. This disclosure is not addressed at Pseudoephedrine HCI as an ingredient in combination with the other excipients.<br>
[009]	U.S. Patent 5,175,002 is addressed at a suspension formulation<br>
comprising soybean oil, lecithin and wax. However the active in this formulation is Amantidine Hydrochloride.<br>
[0010]	U.S.  Patent 5,112,602 to Beurline et al. discloses an oral<br>
pharmaceutical liquid suspension comprised of theophyline as the active agent, silicon dioxide, a wetting agent and a hydrocolloid gum.<br>
Summary of the Invention<br>
[0011]	Accordingly we sought to device a soft gelatin capsule<br>
formulation of Pseudoephedrine HCI because of a variety of reasons. Primarily it is relatively difficult to extract Pseudoephedrine or Ephedrine from a soft gel drug delivery device. Another reason is that a soft gelatin capsulated formulation provides better patient compliance.<br>
[0012]	In accordance with one preferred embodiment there are<br>
provided soft gelatin capsules of a pharmaceutical formulations comprising 60 mg by weight of Pseudoephedrine HCI, 10-20 mg by weight of yellow bees wax, 15-25 mg by weight of partially hydrogenated oil, 2-8 mg by weight of lecithin, 2-8 mg by weight of silicon dioxide and 150-250 mg by weight of soybean oil.<br>
[0013]	In accordance with another preferred embodiment there<br>
are provided methods of making a pharmaceutical formulation comprising the steps of preparing an oily matrix consisting of soybean oil and partially hydrogenated vegetable oil, the oily blend is heat treated with beeswax, to have the beeswax dissolved into the matrix, the steps further comprises blending lecithin to said oily matrix and mixing the active pharmaceutical ingredient into the said matrix. Colloidal silicon dioxide is added to the complex to form a homogeneous blend and the resultant pharmaceutical complex is enclosed into to a capsule, wherein used is 60 mg by weight of Pseudoephedrine HCI, 10-20 mg by weight of yellow bees wax, 15-25 mg by weight of partially hydrogenated oil, 2-8 mg by weight of lecithin, 2-8 mg by weight of silicon dioxide and 150-250 mg by weight of soybean oil. Also is the preferred embodiment to dispose the said pharmaceutical complex into a soft gelatin drug delivery device.<br>
[0014]	It is a principal advantage of the preferred embodiment<br>
that the active ingredient in this formulation is coated with wax, making the possible extraction of Pseudoephedrine and its derivatives further difficult. Yet another advantage of the preferred embodiment is that the drug delivery of the pharmaceutical formulation is achieved by a soft gelatin capsule and this makes it relatively difficult for someone to extract the active unlike the case of a tablet as an OTC drug product. Hence the possibility of abuse of the drug is minimized.<br>
[0015]	It is also an advantage of the preferred embodiment that<br>
the formulation comprises of excipients like yellow beeswax and soybean oil, which are natural substances that make the extraction further difficult. This, in conjunction with the soft gelatin encapsulation makes it relatively a complex multi step process to extract pseudoephedrine from the oily matrix. Thus this preferred embodiment considerably minimizes the potential to abuse the drug product.<br>
Detailed Description of the Preferred Embodiment<br>
[0016]	The    present    invention    relates    to    pharmaceutical<br>
formulations comprising Pseudoephedrine HCI for oral administration in the form of soft gelatin capsules. The formulation also comprises of partially hydrogenated vegetable oil, yellow bees wax, colloidal silicon dioxide, soybean oil and lecithin. We have used soybean oil in the preferred embodiment as a suspension medium and yellow bees wax as a suspending agent. Hydrogenated vegetable oil has been used as a viscosity inducing agent and colloidal silicon dioxide is used to achieve uniform dose dispersion.<br>
[0017]	According to the preferred embodiment, wax forms part of<br>
the fill composition that is inside the gelatin shell. A coating of the product in wax and oil mixture is achieved making it difficult to isolate the active from the formulation.<br>
[0018]	The following examples illustrate preferred embodiments<br>
of pharmaceutical compositions comprising Pseudoephedrine HCI as principal ingredient.<br>
EXAMPLES<br>
Example 1<br>
Ingredients	Composition by weight<br>
Pseudoephedrine HCI, DSP	60 mg<br>
Yellow Beeswax	10-20 mg<br>
Partially Hydrogenated Vegetable Oil	15-25 mg<br>
Lecithin, NF	2-8 mg<br>
Colloidal Silicon Dioxide	2-8 mg<br>
Soybean Oil, USP	150-250 mg<br>
[0019] In general, gelatin capsule formulations for soft gelatin capsule comprise raw gelatin, plasticizer, solvent and optional ingredients such as flavors and colorants. Typically the plasticizer includes glycerin or sorbitol. The preferred plasticizer in this case is glycerin. One preferred gelatin formulation for the soft gelatin capsule used in accordance with preferred embodiment includes gelatin in the range of 40-45 % and a plasticizer in the range of 18-25 %. Capsule formulation can also include other suitable additives, which impart specific characteristics such as the look and feel of the capsule.<br>
[0020]	The following examples illustrate preferred embodiments<br>
of several soft-gelatin-shell Pseudoephedrine HCI formulations. These examples illustrate particular embodiments of the invention and are not intended to limit the scope of the invention in any way.<br>
Example 2<br>
Ingredient	Percentage by weight<br>
Gelatin	43.4%<br>
Glycerin	20.0%<br>
Water	36.6%<br>
Example 3<br>
Ingredient	Percentage by weight<br>
Gelatin	58.5%<br>
Glycerin	31.5%<br>
Water	10.0%<br>
[0021]	Certain modifications and improvements of the disclosed<br>
invention will occur to those skilled in the art without departing from the scope of invention, which is limited only by the appended claims.<br><br><br><br><br>
What is claimed is:<br>
1.	An orally administrable pharmaceutical formulation comprising<br>
an active pharmaceutical ingredient embedded into an oily matrix, viscosity<br>
imparting agents, surfactant; suspending agent; and suspension medium.<br>
2.	The orally administrable pharmaceutical formulation according<br>
to   claim1,    wherein    the   said    active    pharmaceutical    ingredient   is<br>
Pseudoephedrine Hydrochloride.<br>
3.	The orally administrable pharmaceutical formulation according<br>
to   claim1,   wherein   the   said   viscosity-imparting   agents   are   partially<br>
hydrogenated vegetable oil and colloidal silicon dioxide.<br>
4.	The orally administrable pharmaceutical formulation according<br>
to claiml, wherein the said surfactant is lecithin.<br>
5.	The orally administrable pharmaceutical formulation according<br>
to claim1, wherein the said suspending agent is yellow beeswax.<br>
6.	The orally administrable pharmaceutical formulation according<br>
to claim1 , wherein the said suspension medium is soybean oil.<br>
7.	An orally administrable pharmaceutical formulation comprising<br>
as its ingredients:<br>
about 60 mg by weight of Pseudoephedrine HCI,<br>
about 1 0-20 mg by weight of yellow beeswax,<br>
about 15-25 mg by weight of partially hydrogenated vegetable<br>
oil,<br>
about 2-8 mg by weight of lecithin,<br>
about 2-8 mg by weight of colloidal silicon dioxide; and<br>
about 150-250 mg by weight of soybean oil.<br>
8.	The orally administrable pharmaceutical formulation according<br>
to claim 7, wherein the surfactant is employed to provide lubricity to the<br>
matrix.<br>
9.	The orally administrable pharmaceutical formulation according<br>
to claim? or 8, wherein the said oily matrix-embedded active pharmaceutical<br>
complex is disposed into a capsule.<br>
10.	The orally administrable pharmaceutical formulation according<br>
to claim9, wherein the said capsule is a soft gelatin capsule.<br>
11.	The orally administrable pharmaceutical formulation according<br>
to claim7, wherein the said partially hydrogenated vegetable oil and colloidal<br>
silicon dioxide are employed as agents to enhance viscosity.<br>
12.	A process for preparing an orally administrable pharmaceutical<br>
formulation comprising preparing an oily matrix consisting of soybean oil and<br>
partially hydrogenated vegetable oil, heat treating the oily blend with beeswax<br>
enabling the beeswax to dissolve into the oily matrix, blending lecithin to the<br>
oily matrix, mixing the active pharmaceutical ingredient with the matrix, adding<br>
to the matrix colloidal silicon dioxide to form a homogeneous blend thereof<br>
and disposing the resultant pharmaceutical complex into a capsule.<br>
13.	The     process    for    preparing     an     orally    administrable<br>
pharmaceutical formulation according to claim 12, wherein the said active<br>
pharmaceutical ingredient is Pseudoephedrine Hydrochloride.<br>
14.	The   process   for   preparing   of   an   orally   administrable<br>
pharmaceutical formulation according to claim 12, wherein the said capsule is<br>
a soft gelatin capsule.<br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5LWRlbC0yMDAyLWFic3RyYWN0LnBkZg==" target="_blank" style="word-wrap:break-word;">129-del-2002-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5LWRlbC0yMDAyLWNsYWltcy5wZGY=" target="_blank" style="word-wrap:break-word;">129-del-2002-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5LWRlbC0yMDAyLWNvcnJlc3BvbmRlbmNlLW90aGVycy5wZGY=" target="_blank" style="word-wrap:break-word;">129-del-2002-correspondence-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5LWRlbC0yMDAyLWNvcnJlc3BvbmRlbmNlLXBvLnBkZg==" target="_blank" style="word-wrap:break-word;">129-del-2002-correspondence-po.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5LWRlbC0yMDAyLWRlc2NyaXB0aW9uKGNvbXBsZXRlKS5wZGY=" target="_blank" style="word-wrap:break-word;">129-del-2002-description(complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5LWRlbC0yMDAyLWZvcm0tMS5wZGY=" target="_blank" style="word-wrap:break-word;">129-del-2002-form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5LWRlbC0yMDAyLWZvcm0tMTMucGRm" target="_blank" style="word-wrap:break-word;">129-del-2002-form-13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5LWRlbC0yMDAyLWZvcm0tMTkucGRm" target="_blank" style="word-wrap:break-word;">129-del-2002-form-19.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5LWRlbC0yMDAyLWZvcm0tMi5wZGY=" target="_blank" style="word-wrap:break-word;">129-del-2002-form-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5LWRlbC0yMDAyLWZvcm0tMy5wZGY=" target="_blank" style="word-wrap:break-word;">129-del-2002-form-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5LWRlbC0yMDAyLWZvcm0tNS5wZGY=" target="_blank" style="word-wrap:break-word;">129-del-2002-form-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5LWRlbC0yMDAyLWdwYS5wZGY=" target="_blank" style="word-wrap:break-word;">129-del-2002-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5LWRlbC0yMDAyLXBldGl0aW9uLTEzOC5wZGY=" target="_blank" style="word-wrap:break-word;">129-del-2002-petition-138.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="217100-water-treatment-device.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="217102-methods-and-apparatus-for-transfer-switch.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>217101</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>129/DEL/2002</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>13/2008</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>31-Mar-2008</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>24-Mar-2008</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>20-Feb-2002</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>STRIDES INC.</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>37 VERONICA AVENUE, SOMERSET, NJ 08873, U.S.A.</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>RADHAKRISHNAN, RAMACHANDRAN</td>
											<td>B-1/1202, L&amp;T &quot;SOUTH CITY&quot; APPARTMENT, BANNERGHATA ROAD, BANGALORE-560076, INDIA.</td>
										</tr>
										<tr>
											<td>2</td>
											<td>GADDIPATI, NEHRU, BABU</td>
											<td>24 STRATFORD DRIVE, SOMERSET, NJ 08873, U.S.A.</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61J 3/07</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>N/A</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td></td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td></td>
									<td></td>
								    <td>NA</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/217101-process-for-preparing-an-orally-administrable-pharmaceutical-formulation by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 11:22:57 GMT -->
</html>
